



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/626,096	07/26/2000	Robert M Umek	067456-5030US	8157
67374	7590	07/26/2007	EXAMINER	
MORGAN, LEWIS & BOCKIUS, LLP			CALAMITA, HEATHER	
ONE MARKET SPEAR STREET TOWER			ART UNIT	PAPER NUMBER
SAN FRANCISCO, CA 94105			1637	
MAIL DATE		DELIVERY MODE		
07/26/2007		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/626,096	UMEK ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Heather G. Calamita, Ph.D.	1637	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

1)  Responsive to communication(s) filed on 12 February 2007.

2a)  This action is **FINAL**.                            2b)  This action is non-final.

3)  Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

4)  Claim(s) 60-69 is/are pending in the application.  
4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
5)  Claim(s) \_\_\_\_\_ is/are allowed.  
6)  Claim(s) 60-69 is/are rejected.  
7)  Claim(s) \_\_\_\_\_ is/are objected to.  
8)  Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

9)  The specification is objected to by the Examiner.

10)  The drawing(s) filed on \_\_\_\_\_ is/are: a)  accepted or b)  objected to by the Examiner.

    Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

    Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)  The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12)  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a)  All    b)  Some \* c)  None of:  
1.  Certified copies of the priority documents have been received.  
2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3.  Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1)  Notice of References Cited (PTO-892)  
2)  Notice of Draftsperson's Patent Drawing Review (PTO-948)  
3)  Information Disclosure Statement(s) (PTO/SB/08)  
    Paper No(s)/Mail Date \_\_\_\_\_

4)  Interview Summary (PTO-413)  
    Paper No(s)/Mail Date. \_\_\_\_\_

5)  Notice of Informal Patent Application

6)  Other: \_\_\_\_\_

## DETAILED ACTION

### *Continued Examination Under 37 CFR 1.114*

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on February 12, 2007, has been entered.

### *Status of Application, Amendments, and/or Claims*

2. Claims 60-69 are currently pending and under examination. All arguments have been fully considered and thoroughly reviewed, but are deemed not persuasive for the reasons that follow. Any objections and rejections not reiterated below are hereby withdrawn.

### *Claim Rejections - 35 USC § 103*

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 60-69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kayyem et al. (WO 98/20162) in view of Shuber (USPN 5,633,134).

With regard to claim 60, Kayyem et al. teach a method of determining the identification of nucleotide(s) at a first detection position in a first domain of a target sequence, said target sequence comprising said first domain and a second domain, said method comprising:

a. providing an electrode with a covalently attached capture probe, wherein said capture probe has a sequence substantially complementary to said second domain of said target sequence (see p. 36 lines 10-22)

b. contacting said electrode with:

(i) said target sequence;

(ii) a first label probe substantially complementary to said first domain, comprising a first nucleotide at an interrogation position and a first electron transfer moiety (ETM) with a first redox potential (see p. 36 lines 10-22);

With regard to claim 63, Kayyem et al. teach an array of capture probes (see p. 36 lines 10-14, where the plurality of oligomers attached to a plurality of nucleic acids on a plurality of electrodes comprises the array).

With regard to claim 64, Kayyem et al. teach the first label probes contains a plurality of first ETMs (see p.36 lines 30-32).

With regard to claims 66-69, Kayyem et al. teach a ferrocene derivative (see p.41 line 21-24, where a substituted ferrocene is a ferrocene derivative and a transition metal ETM).

Kayyem et al. do not teach step (iii) a second label probe complementary to the first domain comprising a second nucleotide at said interrogation position.

With regard to claim 61, Kayyem et al. do not teach a third label probe complementary to the first domain comprising a third nucleotide at said interrogation position

With regard to claim 62, Kayyem et al. do not teach a fourth label probe complementary to the first target domain comprising a fourth nucleotide at said interrogation position.

Shuber teaches allele specific oligonucleotide hybridization using allele specific oligonucleotide probes.

With regard to claim 60, Shuber teaches multiple oligonucleotide probes with labels for determining nucleotides at the detection position (see abstract and col. 5 lines 13-21 and table 1, where the ASO are the labeled probes used to detect the mutations at the interrogation position)

With regard to claims 62 and 65, Shuber teach multiple probes (see col. 5 table 1, which comprises the multiple labeled probes).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to use the ETM labeled oligonucleotides, as taught by Kayyem et al. with the multiple oligonucleotide probes for mutation detection, as taught by Shuber since Kayyem states, "In general electron transfer between electron donors and acceptors does not occur at an appreciable rate when the nucleic acid is single stranded, nor does it occur appreciably unless nucleotide base pairing exists in the double stranded sequence between the electron donor and acceptor in the double helical structure (see p. 9 lines 21-24)." An ordinary practitioner would have been motivated to use ETM labeled oligonucleotides, as taught by Kayyem et al. with the multiple oligonucleotide probes for mutation detection because Kayyem states that no electron transfer occurs unless nucleotide base pairing exists in the double stranded sequence between the electron donor and acceptor. This property is particularly advantageous for the detection of nucleotide mutations using the multiple probe methods as describe by Shuber in allele specific oligonucleotide hybridization.

### ***Response to Arguments***

3. Applicants' arguments with respect to the rejections over Kayyem and Schuber have been fully considered but they are not persuasive.

Applicants argue neither Kayyem nor Schuber teach a first and second labeled probes that are both complementary to the same domain. Applicants argue claim 60 requires two probes compete for the same hybridization domain but requires the two probes have different nucleotide at the interrogation position. This is not persuasive because claim 60 requires only that the probes are complementary to the same domain. Additionally, Shuber teaches ASO probes which are used to detect mutations at multiple interrogation positions. The interrogation position of Shuber is the base which basepairs with the detection position and in Schuber there are multiple detection positions. Applicants point to p. 12 lines 9-13 –14 of the specification to assert that the interrogation position is the same, however in lines 13-14 the specification indicates the detection position my comprise a plurality of nucleotides...either contiguous or separated and at p. 12 line 13-14 state the interrogation position is the base which base pairs with the detection position and as described in the specification the detection position may comprise a plurality of nucleotides...either contiguous or separated. Therefore the probes of Shuber meet the limitation of claim 60 in that Shuber teaches multiple oligonucleotide probes specific for one domain and this is the only requirement of the claim. Shuber teach multiple oligonucleotide probes with labels for determining nucleotides at the detection position at col. 5 lines 13-21. Here Shuber describes ASOs (labeled probes) which are used to detect mutations at multiple interrogation positions. Shuber teaches the probes are complementary to different mutations sites of the same gene or same sequence. According to the instant specification multiple detection positions are permitted. The rejections are therefore maintained.

#### Summary

4. No claims allowed.

#### *Conclusion*

5. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

Art Unit: 1637

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

*Correspondence*

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Heather G. Calamita whose telephone number is 571.272.2876 and whose e-mail address is [heather.calamita@uspto.gov](mailto:heather.calamita@uspto.gov). However, the office cannot guarantee security through the e-mail system nor should official papers be transmitted through this route. The examiner can normally be reached on Monday through Thursday, 7:00 AM to 5:30 PM.

If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at 571.272.0782.

Papers related to this application may be faxed to Group 1637 via the PTO Fax Center using the fax number 571.273.8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to 571.272.0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

hgc

TERESA E. STRZELECKA, PH.D.  
PRIMARY EXAMINER

*Teresa Strzelecka*  
7/19/07